Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026
MWN-AI** Summary
Intellia Therapeutics presented significant findings regarding its investigational therapy, Lonvoguran Ziclumeran (lonvo-z), for Hereditary Angioedema (HAE) during the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) in Philadelphia. The data highlighted in four posters, accessible on Intellia's website, emphasized the long-term efficacy and safety of a one-time 50 mg dose of lonvo-z.
The lead poster, presented by Dr. Markus Magerl, showcased a pooled Phase 1/2 analysis of 32 HAE patients, demonstrating a remarkable 96% reduction in monthly attack rates, with an impressive 97% of participants remaining attack-free for periods ranging from 2 months to 3 years. The sustained effects were coupled with significant reductions in plasma kallikrein levels, critical for managing HAE.
Dr. Aleena Banerji focused on evolving treatment goals for HAE, noting that a significant portion of patients (86%) achieved attack-free and long-term prophylaxis status beyond 6 months post-treatment—aligning with goals expressed by both clinicians and patients for minimizing treatment burdens.
Furthermore, Dr. Allen Kaplan explained a quantitative systems biology model that correlates excessive kallikrein generation in HAE patients to symptom severity. This model reinforced findings that reducing prekallikrein could restore normal ranges of bradykinin, aligning with clinical outcomes observed with lonvo-z treatment.
Finally, Dr. Paula Busse presented real-world challenges faced by HAE patients, revealing that a quarter reported monthly attacks despite ongoing prophylaxis. The survey underscored the importance of eliminating long-term medication reliance, aiming for therapies that enhance efficacy and patient quality of life.
Lonvo-z, based on pioneering CRISPR technology, is currently undergoing further testing in the Phase 3 HAELO trial, with a vision to transform HAE therapy into an effective one-time treatment modality.
MWN-AI** Analysis
Intellia Therapeutics (NASDAQ: NTLA) has garnered significant attention following its recent presentation at the 2026 AAAAI Annual Meeting, where it unveiled promising long-term clinical data for its CRISPR-based gene therapy, Lonvoguran Ziclumeran (Lonvo-z). The results from a pooled Phase 1/2 clinical analysis demonstrate a dramatic 96% reduction in Hereditary Angioedema (HAE) attacks across a patient group observed for up to three years, indicating Lonvo-z's potential to redefine HAE treatment paradigms.
The data emphasizes long-term durability and safety, with an impressive 97% of participants remaining attack-free. Given the prevalence of chronic treatment regimes among HAE patients, Lonvo-z's one-time administration could appeal strongly to both patients and healthcare providers looking to improve quality of life while minimizing treatment burdens. This unique offering positions Intellia favorably in a market ripe for innovation as ongoing management of HAE through chronic therapies remains a significant challenge.
Investors should consider a few critical factors while gauging Intellia’s stock trajectory. First, the ongoing Phase 3 trial (HAELO) will be pivotal in validating the drug's long-term efficacy and safety for broader regulatory approval. Additionally, pending regulatory designations from the FDA and EMA, including Orphan Drug and Prime Designation, further enhance the commercial viability of Lonvo-z and may bolster stock performance.
However, as with any clinical-stage biopharmaceutical company, potential volatility lies ahead. Market responses to trial results and regulatory milestones can be swift and unpredictable. Thus, investors should carefully monitor not only upcoming data releases but also broader trends in the biotechnology sector, including funding landscapes and competitive pressures.
In conclusion, Intellia Therapeutics presents an intriguing investment opportunity, particularly for those willing to embrace the inherent risks associated with biopharmaceutical development. With Lonvo-z's promising data and its innovative approach to HAE, the company holds the potential to establish significant market relevance in the coming years.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
CAMBRIDGE, Mass., March 03, 2026 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced details about its presentation of four posters at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting (AAAAI) that took place this past weekend in Philadelphia, Pennsylvania. All posters are available on intelliatx.com on the Scientific Publications & Presentations page.
Poster Presentation Details:
- Title: Long-Term Durability and Safety of Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002) 50 mg in Patients with Hereditary Angioedema
Session: Allergic Skin Diseases
Poster Number: 061
Presenter: Markus Magerl, M.D, Professor, Head of Clinical Trials, Charité - Universitätsmedizin Berlin Institute of Allergology- In this pooled Phase 1/2 analysis (n=32), a one-time 50 mg dose of lonvo-z led to deep, stable and durable reductions in plasma kallikrein across all patients with up to three years of follow-up.
- Across the 32 patients, the mean monthly attack rate was consistently ?0.2, representing a mean reduction of 96% in HAE attacks from baseline through last follow-up. Of the 32 patients, 31 (97%) were both attack-free and LTP-free as of the data cutoff, with the attack-free and LTP-free periods ranging from 2 months to 3 years with follow-up ongoing.
- Title: Evolving Treatment Goals to Achieve Freedom from Attacks and Long-Term Prophylaxis Following a One-Time Treatment with Lonvoguran Ziclumeran (Lonvo-z; NTLA-2002)
Session: Allergic Skin Diseases
Poster Number: 005
Presenter: Aleena Banerji, M.D., Professor at Harvard Medical School, Clinical Director of the Allergy and Clinical Immunology Unit at Massachusetts General Hospital- Recent research shows that achieving an attack-free status and simultaneously minimizing treatment burden are primary treatment goals for HAE experts and patients.
- Of the 28 patients with >6 months of follow-up after receiving a one-time 50 mg treatment of lonvo-z in a pooled Phase 1/2 analysis, 86% were attack-free and LTP-free for >6 months, a timeframe suggested by patients to be clinically meaningful.
- Title: Quantitative Systems Biology Modeling Estimates Extent of Excessive Kallikrein Generation in Hereditary Angioedema Patients
Session: Allergic Skin Diseases
Poster Number: 003
Presenter: Allen Kaplan, M.D., Professor, Department of Medicine, Medical University of South Carolina- This model suggested that HAE with significant C1-esterase inhibitor deficiency generates excess plasma kallikrein compared to healthy individuals, directly correlating with bradykinin increases.
- In this model, an 85% reduction in prekallikrein was shown to reduce peak free kallikrein and peak bradykin to near normal ranges. This level of reduction in prekallikrein is consistent with what has been observed clinically with a 50 mg dose of lonvo-z.
- Title: Chronic Medications Pose Challenges for People Living with Hereditary Angioedema
Session: Bridging Evidence for Real World Impact
Poster Number: 716
Presenter: Paula Busse, M.D., Professor, Department of Medicine, Division of Clinical Immunology, Mount Sinai Hospital- Among 100 surveyed U.S. patients with HAE, 89% of whom were on long-term prophylaxis therapies and 11% of whom were on on-demand therapies only, 34% reported having at least one attack per month and only 20% reported being attack free in the prior year.
- Most respondents indicated that eliminating lifetime chronic medication use and enhancing efficacy are the most important ways to improve their current therapy.
About Lonvo-z
Based on Nobel Prize-winning CRISPR/Cas9 technology, lonvo-z has the potential to become the first one-time treatment for hereditary angioedema (HAE). Lonvo-z is an investigational in vivo CRISPR-based gene editing therapy that is currently being investigated in HAELO, a Phase 3 clinical trial in HAE, and is designed to prevent HAE attacks by inactivating the kallikrein B1 (KLKB1) gene, which encodes for prekallikrein, the kallikrein precursor protein. Interim Phase 1/2 clinical data showed dramatic reductions in attack rate, as well as consistent, deep and durable reductions in kallikrein levels. Lonvo-z has received five notable regulatory designations, including Orphan Drug and RMAT Designation by the U.S. Food and Drug Administration (FDA), the Innovation Passport by the U.K. Medicines and Healthcare products Regulatory Agency (MHRA), Priority Medicines (PRIME) Designation by the European Medicines Agency, as well as Orphan Drug Designation (ODD) by the European Commission.
About Intellia Therapeutics
Intellia Therapeutics, Inc. (NASDAQ:NTLA) is a leading clinical-stage biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies. The company’s mission is to transform the lives of people with severe diseases by developing and commercializing potentially curative treatments. With deep scientific, technical and clinical development experience, Intellia aims to reset the standard for medicine by durably treating the root causes of disease. Learn more at intelliatx.com and follow us @intelliatx.
Contact:
Jason Fredette
Vice President, Investor Relations and Corporate Communications
Intellia Therapeutics, Inc.
jason.fredette@intelliatx.com
FAQ**
How does the recent data presented by Intellia Therapeutics Inc. (NTLA) at the AAAAI Annual Meeting support the long-term efficacy and safety of Lonvoguran Ziclumeran in treating hereditary angioedema?
What are the implications of achieving an 86% attack-free rate in patients treated with Lonvoguran Ziclumeran as noted by Intellia Therapeutics Inc. (NTLA) for future treatment protocols in hereditary angioedema?
Can you clarify how the quantitative systems biology modeling discussed by Intellia Therapeutics Inc. (NTLA) correlates excessive kallikrein production with hereditary angioedema outcomes?
In light of the survey results presented by Intellia Therapeutics Inc. (NTLA), how might the findings influence the development of new therapies aimed at reducing chronic medication use in hereditary angioedema patients?
**MWN-AI FAQ is based on asking OpenAI questions about Intellia Therapeutics Inc. (NASDAQ: NTLA).
NASDAQ: NTLA
NTLA Trading
-1.09% G/L:
$12.98 Last:
1,674,598 Volume:
$12.73 Open:
